AI Science Tracker
EN

Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2.

Not stated in the abstract reviewed · 30 Apr 2021 · medicine

Discovery

Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2.

Source check: Source checked. Not independent scientific confirmation.

Finding: A UNet-inspired deep-learning model segmented invasive cribriform carcinoma on prostate H&E slides, enabling a computed cribriform area index (CAI). In a four-site cohort, higher CAI was associated with biochemical recurrence among ICC-positive cases (adjusted HR 1.19 per doubling, p=0.018); discrimination was modest and the association was weak in the overall cohort.

Technology: A UNet-inspired deep-learning segmentation model was trained on 325 annotated image tiles from 36 patients and applied to tumor regions; CAI is the proportion of annotated tumor area classified as cribriform carcinoma.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
A UNet-inspired deep-learning segmentation model was trained on 325 annotated image tiles from 36 patients and applied to tumor regions; CAI is the proportion of annotated tumor area classified as cribriform carcinoma.
Test and result
Among 411 patients with ICC morphology, CAI had c-index 0.62; doubling CAI was independently associated with biochemical recurrence among 298 ICC-positive patients (HR 1.19, 95% CI 1.03–1.38, p=0.018). Overall-cohort discrimination was weak (c-index 0.54).
Limitation / still unknown
The segmentation model was applied to a multi-institutional validation cohort of 749 patients; the source reports site-level patterns and recurrence associations. The modest discrimination and retrospective association do not establish clinical utility.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8419103/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.